NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. The company’s lead product is Zecuity, which is a sumatriptan iontophoretic transdermal system used for the acute treatment of migraine with or without aura in adults. Its pipeline product candidates include NP201 for the continuous symptomatic treatment of Parkinson's disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The company develops its products using SmartRelief, a proprietary transdermal medication delivery technology based on iontophoresis, a non-invasive method of actively transporting molecules, such as sumatriptan; and Long-Acting Delivery, a biodegradable polymer matrix, which uses medical polymers and an active drug combined to form a small implant for injection just below the skin. NuPathe Inc. was founded in 2005 and is based in Malvern, Pennsylvania. As of February 20, 2014, NuPathe, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.